Skip to main content
Federal Circuit· 3/22/2007

Pfizer, Inc. v. Apotex, Inc.

Citations

  • 480 F.3d 1348
  • 82 U.S.P.Q. 2d (BNA) 1321
  • 2007 U.S. App. LEXIS 6623
  • 2007 WL 851203

How courts have described this case

Verbatim parenthetical descriptions written by other courts when citing this decision. Ranked by citation-network relevance.

  • stating that for purposes of obviousness, the relevant teachings can be \found in any number of sources\
  • noting that the “burden of proof never shifts to the patentee to prove validity” (citation omitted)
  • emphasizing that “the discov- ery of an optimum value of a variable in a known process is usually obvious”
  • holding the district court clearly erred when it failed to consider relevant prior art
  • collecting cases and explaining that “obviousness cannot be avoided simply by a showing of some degree of unpredictability in the art so long as there was a reasonable probability of success”
  • “Even if Pfizer showed that amlodipine besylate exhibits unexpectedly superior results, this secondary consideration does not overcome the strong showing of obviousness in this case.”

Source: CourtListener parenthetical corpus (CC0).

Judges: Linn, Mayer, Michel

Read full opinion on CourtListener

Cited by

174 cases in this archive cite this case; the 20 most cited are listed.

Cites

49 cases in this archive are cited by this case; the 20 most cited are listed.

Other cases named Pfizer, Inc. v. Apotex, Inc.

5 other CourtListener records share this case name.

Sourced from CourtListener / Free Law Project (CC0).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.